March 13, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Accelerate Diagnostics Inc (NASDAQ:AXDX) shares over potential securities laws violations by Accelerate Diagnostics and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Accelerate Diagnostics Inc (NASDAQ:AXDX) concerning whether Accelerate Diagnostics may have issued materially misleading business information to the investing public.

Accelerate Diagnostics Inc reported that its Net Loss increased from $15.28 million in 2013 to $30.93 million in 2014. Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) grew from under $1 per share in April 2012 to as high as $30.08 per share in June 2014, respectively $28.78 per share in October 2014.

On February 18, 2015, an article was published that asserted that Accelerate Diagnostics Inc falsely claimed that it had developed a technique for diagnosing pathogens in a blood sample without a need for using a blood culture, while in reality, the test required a blood culture, a fact that significantly reduced the value of the technology. Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX0 declined to as low as $17.29 per share on February 23, 2015.